This prospective, multicenter, randomized trial compared the paclitaxel-eluting balloon versus everolimus-eluting stent to treat patients with in-stent restenosis. 309 patients were included in total (154 received the drug-eluting balloon, and 155 received the everolimus-eluting stent). There were no differences in the characteristics of both groups. At one year the rate of cardiac death, myocardial infarction<a href="https://solaci.org/en/2015/06/24/ribs-iv-drug-eluting-balloon-versus-everolimus-eluting-stent-on-in-stent-restenosis/" title="Read more" >...</a>

This study evaluated the performance of Nobori biolimus bio-absorbable polymer stent in real-world patients. A total of 3067 consecutive patients followed up to 5 years were included. The rate of target lesion (composite of cardiac death, myocardial infarction and target lesion revascularization) was 3.9% at one year and 5.1% at 2 years. Long-term clinical performance<a href="https://solaci.org/en/2015/06/24/nobori-ii-final-5-year-results-of-drug-eluting-stent-with-bio-absorbable-polymer/" title="Read more" >...</a>

TRYTON is a cobalt chromium device specifically dedicated for bifurcation lesions to be implanted in the side branch. Circumflex artery is the major lateral branch fund the coronary tree. Between 2008 and 2011 this work included 52 patients with left main coronary unprotected lesions who underwent angioplasty with drug-eluting stent in the coronary trunk left<a href="https://solaci.org/en/2015/06/24/tryton-dedicated-bifurcation-stent-in-left-main-coronary-artery/" title="Read more" >...</a>

Previous studies suggest the excellent performance of the bioactive coated stent TITAN 2 compared with drug-eluting stents (DES). The aim of the study was to evaluate the results of this device in patients undergoing both ST segment elevation and without ST segment elevation acute coronary syndrome. A total of 1066 patients were included, of whom<a href="https://solaci.org/en/2015/06/24/titan-ami-final-results-of-bio-active-coated-stent/" title="Read more" >...</a>

This study randomized 2:1 &#8211; 2707 patients to biolimus eluting stent with biodegradable polymer versus everolimus eluting stent with permanent polymer. At one year, the results were similar demonstrating the biolimus eluting stent noninferiority. At three years cardiac death, myocardial infarction and target vessel revascularization rates remained similar with 11% for biolimus eluting stent and<a href="https://solaci.org/en/2015/06/24/compare-ii-biolimus-eluting-stent-with-biodegradable-polymer-versus-everolimus-at-3-years/" title="Read more" >...</a>

The PARIS registry was a prospective observational study in 5018 patients undergoing coronary angioplasty with stent implantation in 15 centers. Three categories were prespecified in the discontinuation of dual antiplatelet therapy: 1) discontinuation for medical guidance, 2) transient discontinuation for less than 15 days for surgery and 3) permanent abandonment of it by non-adherence or<a href="https://solaci.org/en/2015/06/24/paris-register-non-adherence-impact-to-antiplatelet-therapy-among-men-and-women/" title="Read more" >...</a>

The aim of this study was to evaluate the safety and efficacy of coronary orbital atherectomy system Diamondback to prepare de novo lesions severely calcified to stent implantation. This orbital atherectomy system is the first approved by the FDA to treat this type of injury, so the study had no control group. The rate of<a href="https://solaci.org/en/2015/06/24/orbit-ii-atherectomy-for-heavily-calcified-lesions/" title="Read more" >...</a>

The aim of this study was to evaluate the performance of the sirolimus eluting stent with bio -absorbable polymer (MiStent SES) compared with zotarolimus eluting stent with permanent polymer (Endeavor). This 2:1 randomized, multicenter study included 183 patients with the primary objective of evaluating the late lumen loss between the MiStent and Endeavor a two<a href="https://solaci.org/en/2015/06/24/dessolve-ii-2-year-results-show-the-superiority-of-the-sirolimus-eluting-stent-with-fast-bio-absorbable-polymer/" title="Read more" >...</a>

P2Y12 receptor inhibitors are effective in patients experiencing NSTE-ACS, however, the administration timing is not clear. This study evaluated the administration of prasugrel at the time of diagnosis of ACS or after performing coronary angiography when angioplasty was already decided. 4033 patients were included experiencing an NSTE-ACS troponin positive who had planned angiography between 2<a href="https://solaci.org/en/2015/06/24/accoast-pretreatment-with-prasugrel-in-non-st-elevation-acute-coronary-syndrome-nste-acs-offers-no-benefit-and-increased-bleeding/" title="Read more" >...</a>

The last results of the SORT OUT V submitted in PCR 2012 showed that biolimus eluting stent with &nbsp;biodegradable polymer was not able to reach the non-inferiority versus sirolimus eluting stent with permanent polymer. Results to 3 years are now available, and &nbsp;the new device reached the non-inferiority with a MACE rate of 11.2% for<a href="https://solaci.org/en/2015/06/24/sort-out-v-similar-results-of-biolimus-eluting-stent-with-biodegradable-polymer-versus-sirolimus-eluting-stent-with-permanent-polymer/" title="Read more" >...</a>